At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 81 enrolled
Drug / intervention
CP-690,550 +7 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PHASE 2A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, INTRA-INDIVIDUAL COMPARISON TRIAL ASSESSING SAFETY, TOLERATION, PHARMACOKINETICS AND PILOT EFFICACY OF 4 WEEKS TREATMENT WITH TOPICAL CP-690,550 IN CHRONIC PLAQUE PSORIASIS
In Brief
A Phase 2 clinical trial evaluating CP-690,550 and Placebo Vehicle for Psoriasis. Completed, enrolled 81 participants across 20 sites in 2 countries.
Detailed Summary
Study will test effectiveness of an experimental drug applied once or twice daily to two psoriasis plaques. Requires 1 clinic visit each week for 5 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2008
Enrollment StartOct 2008
Primary CompletionJul 2009
Study CompletionJul 2009
TodayJul 2026
First PostedMay 15, 2008
Enrollment StartOct 13, 2008
Primary CompletionJul 9, 2009
Study CompletionJul 24, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 18.1 years ago
Interventions
CP-690,550drug
Topical treatment once daily for 28 days
CP-690,550drug
Topical treatment once daily for 28 days
CP-690,550drug
Topical treatment once daily for 28 days
CP-690,550drug
Topical treatment twice daily for 28 days
CP-690,550drug
Topical treatment twice daily for 28 days
CP-690,550drug
Topical treatment twice daily for 28 days
Placebo Vehicledrug
Topical treatment once daily for 28 days
Placebo Vehicledrug
Topical treatment twice daily for 28 days